Abstract Number: 464 • 2014 ACR/ARHP Annual Meeting
Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease
Background/Purpose Certolizumab pegol (CZP) is approved for adult patients (pts) with rheumatic diseases (RA, PsA and AS) at a maintenance dose of 200mg every 2…Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…Abstract Number: 472 • 2014 ACR/ARHP Annual Meeting
Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease
Background/Purpose : Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of…Abstract Number: 446 • 2014 ACR/ARHP Annual Meeting
Immunoglobulin a Antibodies to Cyclic Citrullinated Protein Predominate in Individuals at-Risk for Future Rheumatoid Arthritis
Background/Purpose Immunoglobulin A (IgA) autoantibodies (Abs) to citrullinated proteins (ACPAs) are present in the preclinical period of RA development, a finding that suggests a mucosal…Abstract Number: 445 • 2014 ACR/ARHP Annual Meeting
Differing Specificities of Anticitrullinated Peptide/Protein Antibodies in Palindromic Rheumatism and Rheumatoid Arthritis: A Case-Control Study
Background/Purpose: Palindromic rheumatism (PR) may evolve to rheumatoid arthritis (RA), particularly in patients with citrullinated peptide/protein antibodies (ACPA), although a significant number of patients do…Abstract Number: 444 • 2014 ACR/ARHP Annual Meeting
Evidence for Citrullination of the Nuclear Transciption Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid Arthritis
Background/Purpose: Citrullination is a post-translational modification mediated by peptidyl arginine deiminase (PAD) enzyme in which arginine is converted to citrulline. Inhibitor of DNA binding 1…Abstract Number: 443 • 2014 ACR/ARHP Annual Meeting
Sputum Anti-Citrullinated Protein Antibodies in Patients with Long Standing Rheumatoid Arthritis
Background/Purpose: The lung has been implicated in the pathogenesis of rheumatoid arthritis (RA). The aim of this study was to evaluate the presence of autoantibodies…Abstract Number: 442 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels
Background/Purpose: Recent studies indicate that the breach of immune tolerance that occurs in rheumatoid arthritis (RA) extends beyond the citrullination of arginines (as recognized by…Abstract Number: 441 • 2014 ACR/ARHP Annual Meeting
Arthritis Associated Autoantibodies in Non-Rheumatoid Arthritis Patients with Mucosal Inflammation
Background/Purpose: Rheumatoid arthritis (RA) associated autoantibodies, such as anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and anti-carbamylated protein antibodies (anti-CarP), can be present in serum…Abstract Number: 440 • 2014 ACR/ARHP Annual Meeting
Comparison of C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) with Estimated Glomerular Filtration Rate (eGFR) in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: It has previously been demonstrated that the ESR and CRP correlate in patients with RA but with a high degree of variability. Reasons for…Abstract Number: 439 • 2014 ACR/ARHP Annual Meeting
The Anti-IL-6 Antibody Sirukumab Inhibits Vascular Inflammation in a Human Surrogate Model of Atherosclerosis
Background/Purpose: Rheumatoid arthritis (RA) and atherosclerosis are chronic inflammatory diseases that share many biological features. Prevalence of atherosclerosis is increased by approximately 2-fold in RA,…Abstract Number: 458 • 2014 ACR/ARHP Annual Meeting
Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Serious infection events (SIEs) have been reported in the tofacitinib…Abstract Number: 457 • 2014 ACR/ARHP Annual Meeting
First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Background/Purpose: To evaluate the long-term safety of tocilizumab (TCZ) for the treatment of rheumatoid arthritis (RA) in a real-world clinical setting in Japan. Methods: In…Abstract Number: 456 • 2014 ACR/ARHP Annual Meeting
AAA-Atpase p97 Regulates Autophagy-Associated Cell Death in Arthritis
Background/Purpose: Recently we described a hypersensitivity of rheumatoid arthritis synovial fibroblasts (RASF) compared to osteoarthritis synovial fibroblasts to autophagy under conditions of severe endoplasmic reticulum…Abstract Number: 455 • 2014 ACR/ARHP Annual Meeting
Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis
Background/Purpose Antibodies against carbamylated proteins (CarP) are a new type of autoantibodies specific of patients with rheumatoid arthritis (RA) relative to healthy controls, but their…
ACR Meeting Abstracts